Core Insights - Viva Biotech has been awarded Frost & Sullivan's 2025 APAC Technology Innovation Leadership recognition for its achievements in the Integrated Intelligent Drug Discovery industry, highlighting its role in enhancing preclinical research and development efficiency [2][3] - The company integrates artificial intelligence with laboratory validation to innovate drug discovery processes, thereby strengthening client partnerships and delivering scalable solutions [2][4] Company Overview - Established in 2008, Viva Biotech specializes in providing comprehensive services from early-stage Structure-Based Drug R&D to commercial manufacturing for global biopharmaceutical innovators [10] - The company employs advanced technology platforms and a dedicated team to cover all aspects of therapeutic strategies and drug modalities, including small molecules and biologics [10] Technology and Innovation - Viva Biotech's AI-Driven Drug Discovery (AIDD) platform includes modules such as V-Scepter, V-Orb, and V-Mantle, which address drug design challenges through predictive modeling, physics-based simulations, and generative AI [5][9] - The integrated platform has supported over 150 projects for more than 50 global clients, achieving 30-50% faster discovery and up to 70% cost savings [6] Strategic Vision - The recognition from Frost & Sullivan aligns with Viva Biotech's long-term vision of creating an integrated platform that combines AIDD with structure-based drug discovery (SBDD) [8] - The company aims to continue accelerating AI-driven drug discovery and development, positioning itself as a leader in scientific innovation [8]
Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry